Fibrosis CRO Landscape 2026: 5 Preclinical Providers
Independent comparison of five fibrosis & MASH CROs — Gubra, InSphero, Inotiv, Physiogenex, Charles River — across models, strengths, and use cases.
Lead: In fibrosis and MASH drug development, picking the right preclinical CRO often determines whether your Go/No-Go decision rests on reproducible data or on noise. Every provider's website claims "cutting-edge," "specialized," and "highly reproducible" capabilities — leaving program leaders to guess at the real differences. This article compares five publicly documented preclinical providers in the fibrosis space — Gubra, InSphero, Inotiv, Physiogenex, and Charles River Laboratories — strictly using publicly available information (official websites, press releases, peer-reviewed publications). We do not list prices (direct quotes are always required). Instead, we focus on strengths, available models, and intended use cases so you can triangulate which provider fits your program.
Key Takeaways
- Differentiators, strengths, and weak spots of five specialized fibrosis CROs
- Specific in vivo / in vitro models covered by each (liver, lung, kidney, skin)
- A use-case-driven selection flowchart (MASH deep-dive / IPF / multi-organ screening)
- Four sourcing checks you can perform from public data before signing an NDA
- The 7-axis selection framework for procurement implementation (Fibrosis CRO Selection Criteria 2026)
📢 Editorial Disclosure This article is produced independently by our editorial team. We receive no monetary compensation, sponsored placement, or affiliate revenue from any of the five CROs listed. Ordering and assessments are based on each provider's official website, PubMed-indexed literature, and public press releases. See full disclosure at the end.
1. At-a-Glance: Strengths and Therapeutic Coverage
Let's start with a bird's-eye view. The five providers differ substantially in geography, business model, and depth of indication.
Selection method and limits: This is a practitioner comparison of providers whose models, indications, and operational scope can be verified from public information — not a comprehensive market-share ranking, revenue league table, or recommended-vendor certification. Each provider's "strength" is framed not as a fixed rank but along observable axes such as public-evidence depth, model breadth, regulated-testing infrastructure, and in vitro translational platform.
| CRO | HQ | Primary format | Liver (MASH / Fibrosis) | Lung (IPF) | Kidney (CKD) | Skin (SSc) | Signature |
|---|---|---|---|---|---|---|---|
| Gubra | Denmark | In vivo (mouse) | ◎ (GAN DIO-MASH, STAM, HFMCD, CCl4) | ○ (IPF) | ○ (CKD/DKD/AKI) | △ | Top-ranked GAN MASH model in the LITMUS human-proximity analysis |
| InSphero | Switzerland | 3D in vitro / MPS (platform & service) | ◎ (3D InSight™ Liver, MASH) | — | — | — | 3D spheroids for MoA and screening |
| Inotiv | USA | In vivo (mouse & rat) | ○ (BDL, CCl4, TAA) | ○ (pulmonary) | ○ (renal) | △ | Vertically integrated, multi-organ coverage |
| Physiogenex | France | In vivo (mouse & rat) | ◎ (CCl4, TAA, MASH) | ○ (Bleomycin DIO) | ○ (UUO) | — | 15+ year MASH CRO, unique DIO + Bleomycin IPF |
| Charles River | USA / Global | In vivo + in vitro + research models | ◎ (CDAA, HFHC, biopsy-confirmed) | ◎ (Bleomycin mouse & rat) | ○ (renal: confirm directly) | ○ (Bleomycin scleroderma) | Full-service scale, GLP / regulated testing |
◎ = core service, ○ = offered (confirmed on official site), △ = limited or not explicitly listed, — = not offered
Three business model clusters
- MASH / Fibrosis specialists: Gubra, Physiogenex (15+ years of model validation, deep historical data)
- 3D in vitro platform: InSphero (ideal for compound triage, MoA validation)
- Multi-therapeutic full-service: Inotiv, Charles River (scale, regulatory, IND-enabling)
2. Provider Profiles
2-1. Gubra (Denmark) — Strong, Well-Documented MASH Model Depth
Strengths
- GAN diet–induced DIO-MASH model was ranked among the highest for human proximity by the LITMUS consortium (a major EU/US biomarker initiative); in that analysis the top-ranking models for both MASH-fibrosis and metabolic resemblance were all GAN-diet based (Vacca M et al., Nat Metab 2024, DOI 10.1038/s42255-024-01043-6, PMC11199145)
- Biopsy-confirmed MASH workflow (histology-based randomization before dosing)
- Coverage extends beyond MASH to MASH-HCC, idiopathic pulmonary fibrosis (IPF), obesity, and CKD/DKD/AKI
- Also operates as an AI-native drug discovery company with an internal peptide pipeline
Best for
- IND-enabling efficacy studies for MASH/NASH assets
- Head-to-head comparisons with resmetirom, semaglutide, or tirzepatide
- Studies requiring biopsy-confirmed enrollment (clinical-trial-mimicking design)
Caveats
- Europe-based — factor in animal shipping and time-zone overhead if you are US/Asia based
- Scleroderma (skin) is not explicitly listed on the public services page
Recent updates (Q1 2026)
- Facility expansion: the January 2026 expansion PR announced DTU Science Park lab-capacity expansion (the Q1 2026 trading statement confirms the expanded facilities became operational)
- In the same Q1 trading statement, Gubra lowered its 2026 CRO external-revenue growth outlook from 5–15% to 0–10% and flagged macroeconomic headwinds (notably among smaller biotech clients) — treat this freshness item with both the positive and the cautionary side
📎 Reference: Gubra — Liver / MASH CRO Services / Gubra Q1 2026 trading statement / Gubra facility expansion PR
2-2. InSphero (Switzerland) — 3D Spheroids for Mechanism and Screening
Strengths
- 3D InSight™ Liver Microtissues co-culture primary human hepatocytes with non-parenchymal cells (HSCs, Kupffer cells)
- Akura™ Microplate Technology supports up to 384-well throughput with excellent size/shape uniformity
- Announced a February 2026 partnership with PharmaNest, integrating FibroNest™ AI fibrosis quantification into MASH spheroid readouts
- Ideal before moving to in vivo: compound triage, MoA validation, species bridging
Best for
- Compound prioritization before committing to in vivo studies
- Species-to-human translational bridging (mouse vs human response)
- MoA confirmation and off-target profiling
Caveats
-
Does not offer in vivo efficacy endpoints (no hydroxyproline from tissue, no in vivo imaging). Must be paired with an in vivo CRO
-
Compound solubility/volatility may limit assay compatibility
-
Classified not as an in vivo CRO but as a 3D in vitro / MPS platform and service provider — evaluate it along in vitro screening and translational fibrosis quantification, not as a like-for-like in vivo study vendor
📎 Reference: InSphero / InSphero × PharmaNest partnership PR / InSphero Liver Disease
2-3. Inotiv (USA) — Broad Multi-Organ In Vivo Coverage
Strengths
- Liver fibrosis: BDL (bile duct ligation), CCl4, and TAA all on the menu
- Pulmonary (obstructive, restrictive, vascular) and renal disease models both publicly listed
- Post–Envigo acquisition (completed November 2021), vertically integrated from research model supply through in-life and pathology
- Multiple US sites provide capacity flexibility
Best for
- Multi-organ screening (one compound, liver + lung + kidney in parallel)
- Programs that prefer to consolidate animal supply + study execution with one vendor
- US-market IND-enabling programs
Caveats
- MASH depth is less explicit on the public site than Gubra/Physiogenex (less visible coverage of modern diet models such as CDAA, GAN)
- Quantitative endpoint depth (hydroxyproline, Sirius Red % area) should be confirmed directly for your target
- Obtained minimum liquidity covenant waivers in Q1–Q2 2026 (SEC 8-K, May 4 2026; test dates Mar 6–May 8 2026). The May 11 2026 Form 10-Q discloses going-concern risk (substantial doubt), with term loans and convertible notes classified current due to maturities within 12 months. Operations remain ongoing, but sponsors should include credit risk, prepayment exposure, data/sample transfer, and continuity safeguards in vendor diligence (public model breadth is strong; financial covenant waivers should be checked in diligence)
📎 Reference: Inotiv — Liver Disease Models / Inotiv 2026-05-04 Form 8-K / Inotiv FY2026 Q2 Form 10-Q / Inotiv Envigo acquisition completion PR
2-4. Physiogenex (France) — The NASH/MASH CRO Pioneer
Strengths
- Publicly positions itself as a "Pioneer preclinical CRO in the NASH/MASH and liver fibrosis field" with 15+ years of validated models
- Specific fibrosis models: 4-week CCl4 mouse, 8-week CCl4 rat, TAA rat, UUO mouse, and a Bleomycin-induced IPF DIO mouse (unusual — combines obesity + IPF)
- Deep endpoint menu: ORO / H&E / Sirius Red / Masson Trichrome / IHC (F4/80, CD68, α-SMA, Collagen III) / qPCR / ALT-AST / bile acids / hyaluronic acid / NAS score
- Known for radio-tracer-based lipogenesis and glucose homeostasis mechanism studies
Best for
- MASH assets where liver function + metabolic parameters must be evaluated together
- Radiotracer-based mechanism studies (lipid/glucose flux)
- Obesity-complicated IPF (emerging translational stratification)
Caveats
- Mid-size European operation — parallel-study capacity is smaller than Charles River
- Scleroderma not explicitly listed
📎 Reference: Physiogenex — Fibrosis CRO Services
2-5. Charles River Laboratories (USA, Global) — Full-Service Incumbent
Strengths
- Bleomycin-induced lung fibrosis in both mouse AND rat; published on ex vivo micro-CT translational biomarkers
- MASH colony: CDAA and HFHC diet–induced, biopsy-confirmed mice maintained on standby for rapid study starts
- One of the few CROs publicly offering a Bleomycin-induced mouse model of scleroderma (skin fibrosis)
- Large full-service provider with regulated-testing infrastructure: research model supply, GLP tox, safety assessment, and IND-enabling support (CMC sits outside the scope of a fibrosis-efficacy CRO comparison and is not covered here)
- Note: Charles River's Japan research-model site (Kanagawa, formerly Charles River Laboratories Japan) was divested to The Jackson Laboratory in October 2021 and now operates as JAX Japan. Charles River provides Japanese-language support through global/regional channels, but does not operate a local in vivo fibrosis site in Japan; sponsors needing a JP-local execution footprint should route to JAX Japan.
Best for
- IND-enabling packages that bundle efficacy + toxicology under one MSA (see ICH M3(R2) Roadmap for the full required package)
- Programs requiring in vivo scleroderma models
- GLP-compliant final reports for regulatory submissions
Caveats
- Large-organization dynamics: variable project management experience, longer lead times than niche CROs in some cases
- MASH model currency (newer-generation GAN/AMLN diet models) is less visible on the public site than at Gubra/Physiogenex
- Q1 2026 earnings (2026-05-07): agreed to divest part of European Discovery Services to IQVIA, planned/expected to complete in May 2026 (no completion announcement confirmed as of 2026-05-29). Site/scope and any impact on fibrosis/MASH study capacity should be confirmed directly before contracting (the CDMO/Cell Solutions divestiture closed 2026-05-06, but European Discovery Services is a separate deal — do not treat it as completed)
📎 References: CRL — Pulmonary Fibrosis Models / MASH Models / Bleomycin Scleroderma / CRL Q1 2026 results / CRL planned divestitures PR
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Selection Flowchart
Priority-based shortlist
| Priority | Primary | Secondary |
|---|---|---|
| MASH model depth (LITMUS translatability) | Gubra | Physiogenex |
| IPF (lung fibrosis) depth | Charles River | Gubra / Physiogenex |
| In vitro MoA / screening | InSphero | — |
| Multi-organ parallel screening | Inotiv | Charles River |
| GLP + IND-enabling bundle | Charles River | Inotiv |
| Scleroderma (skin) | Charles River | — |
| Japan-local support | JAX Japan (formerly CRL Kanagawa, divested Oct 2021) | Charles River via global desk (no local JP ops) |
| Obesity-complicated IPF | Physiogenex | — |
4. Four Public-Information Checks Before Your NDA
Before you even sign an NDA, four quick checks against a CRO's public assets will save you weeks of mismatched expectations.
✅ Check 1 — Is there a dedicated fibrosis services page?
Without a dedicated page, you cannot judge background-data depth from public information alone (confirm directly via inquiry). Gubra, Physiogenex, and Charles River all publish dedicated pages.
✅ Check 2 — Are model durations and induction methods explicit?
"CCl4 model" vs. "4-week CCl4 mouse / 8-week CCl4 rat" is a huge trust gap. Explicit parameters imply variant depth and accumulated historical data.
✅ Check 3 — Are quantitative endpoints enumerated?
Sirius Red % area, hydroxyproline, AI-based fibrosis scoring — if the CRO lists specific numerical readouts, they likely deliver them reproducibly. Physiogenex is particularly thorough here.
✅ Check 4 — How fresh is the publication / conference footprint?
Cross-check listed publications on PubMed. Low publication cadence can signal out-of-date protocols; frequent conference presence signals active method refinement.
See the companion guide: CRO Selection Guide: Cost Drivers and a 3-Point Quality Checklist.
5. FAQ
Q1: Is it acceptable to solicit quotes from multiple CROs in parallel? A: Yes — 3-way comparative quoting is industry standard for B2B preclinical outsourcing. After NDAs are signed, being transparent about parallel sourcing usually helps CROs prioritize their response.
Q2: Are there other strong fibrosis CROs besides these five? A: Yes. Biocytogen (China — NASH models), WuXi Biology, Oncodesign Services (France), and several Japan-domestic specialists are credible. We selected these five for depth of public documentation and differentiated specialization.
Q3: Will a CRO share historical background data before NDA? A: Typically only published material (papers, posters, conference abstracts) is shareable pre-NDA. Detailed CV values and individual study data come after NDA. The cadence of public posters and preprints is a useful proxy.
Q4: Why no price information? A: Fibrosis study pricing swings widely with model, N, dosing route, duration, and endpoint count — a fixed number would mislead. Issue an identical spec sheet to all candidates for apples-to-apples quotes. See Cost Drivers for what drives those numbers.
Q5: How often will this article be updated? A: This reflects publicly available information as of May 2026. CROs acquire, spin off, and launch new models frequently. We plan annual refreshes with ad-hoc updates for material changes (acquisitions, service discontinuations).
6. Related Reading
- CRO selection fundamentals
- Indication-specific CRO comparisons (series continues)
- Model selection references
- Quantification methods
Editorial Disclosure
- This article is produced independently by our editorial team
- We receive no monetary compensation, sponsored placement, or affiliate revenue from Gubra, InSphero, Inotiv, Physiogenex, or Charles River Laboratories
- Ordering reflects grouping by business model and geography — not ranking
- Sources: each provider's official website, public press releases, and PubMed-indexed publications (as of May 2026)
- Corrections or updates are welcome via our contact page
Reference sources:
- Gubra — Liver / MASH CRO Services
- InSphero — 3D InSight™ Platform
- Inotiv — Liver Disease Models
- Physiogenex — Fibrosis Preclinical CRO Services
- Charles River — Pulmonary Fibrosis Models
- Charles River — MASH Models
- Charles River — Bleomycin-induced Scleroderma Model
- Vacca M et al. Nat Metab 2024 — LITMUS murine MASLD model ranking (DOI 10.1038/s42255-024-01043-6)